

RESOURCES

PEOPLE

Robert Swanson, one of the co-founders of Genentech (S. San Francisco, CA), has died after a long battle with brain cancer at the age of 52. In 1976, as a 29-year-old venture capitalist with Kleiner Perkins, he and Stanford biochemist Herbert Boyer started Genentech as the first biotechnology company. He served as director and chief executive officer until February 1990, and as chairman of the board until December, 1996. He is survived by his wife and two daughters.



International Isotopes (Denton, TX) has announced the appointment of **David M. Camp** as chief executive officer. Dr. Camp previously served as vice president of Millipore, general manager of the high-performance plastics department for AMOCO Chemical, and manager of operations and development for General Electric.

John P. Feighner has been appointed president and **Robert Budetti** has been appointed chief operating officer of Innapharma (Suffern, NY). Both men were also appointed to the company's board of directors. Dr. Feighner is the founder and president of the Feighner Research Institute, which has conducted clinical trials, predominantly in psychiatric drugs, over the past 26 years. Mr. Budetti has been chief financial officer at the Feighner Institute and International Clinical Research. In addition, **Jeffrey S. Freed** has been appointed senior vice president and managing director of Innapharma. Dr. Freed is associate clinical professor of surgery at Mt. Sinai School of Medicine.

ICON Clinical Research (Dublin, Ireland) has appointed **John W. Hubbard** chief operating officer. Dr. Hubbard was most recently senior vice president, clinical research operations at Innovative Clinical Solutions. He will be based at ICON's North Wales, Pennsylvania office. In addition, the company has also named **Louise M. Murphy** vice president of clinical informatics, based in Irvine, Calif. Previously, Dr. Murphy was vice president, clinical informatics for CoCensys.

GelTex Pharmaceuticals (Waltham, MA) has announced the appointment of two senior directors: **Judith Marquis** joins GelTex as senior director, preclinical development, and **Scott De'Aeth** joins the company as senior director, quality affairs. Dr. Marquis previously held the position of director, preclinical

development at both Hybridon and Procept, and Mr. De'Aeth was most recently director, quality assurance at Glaxo's facility in Zebulon, North Carolina.

IntraBiotics Pharmaceuticals (Mountain View, CA) has named **Liza Page Nelson** to its board of directors, in connection with a recent private placement of shares that raised \$25 million for the company. Ms. Nelson is vice president of Investor AB, which led the round of financing, and was formerly senior director of business development for Pfizer US Pharmaceuticals.

Nathan W. Rosen has been appointed vice president of marketing at SIGA Pharmaceuticals (New York). Mr. Rosen was previously president of Big Idea Productions, the specialty marketing division of J. Walter Thompson.

Therion Biologics (Cambridge, MA) has appointed **Ronald J. Saldarini** to its board of directors. Dr. Saldarini retired in 1999 as president of Wyth-Lederle Vaccines and Pediatrics, a unit of American Home Products. The company also announced the appointment of **Richard Woodrich** to the newly created position of senior vice president of business development. Mr. Woodrich was most recently executive vice president and chief operating officer at CytoMed.

Deborah A. Smeltzer has been named vice president, finance for PE Biosystems (Foster City, CA). She most recently served as CFO and vice president of Genset SA.

Eos Biotechnology (S. San Francisco, CA) has announced two key staff additions: **Victor Solovyev** has been appointed director of bioinformatics and **Asaf Salamov** has been appointed bioinformatics specialist. Both Dr. Solovyev and Dr. Salamov join the company from the Sanger Centre in Cambridge, UK, where Dr. Solovyev led the computational genomics group of the bioinformatics division. In addition, Eos has announced that **David Kristofferson**, director of information systems, recently became a Fellow of the American Association for the Advancement of Science for his work in developing electronic communication systems (the BIOSCI/bionet newsgroup system) for the bioinformatics and biology communities.

Wayne P. Yetter has been appointed to the board of directors of Transkaryotic Therapies (Cambridge, MA). He is currently chief operating officer at IMS Health, and was previously president and chief executive of Novartis Pharmaceutical Corp.